Effects of Single Oral Dose Dapagliflozin QT Study

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The main purpose of this study is to examine the effect of dapagliflozin on electronic measures of heart beats in healthy males

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Bristol-Myers Squibb
• Treatments: Dapagliflozin; Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• Healthy males age 18 to 45 years of age, who are not currently taking any medications

• Normal screening results including a physical examination, laboratory tests, heart rate, blood pressure, and ECG (electronic measure of the heart)

Exclusion Criteria:

• No personal or family history of significant heart problems

• No use of over the counter medications within 7 days of the study

• No use of prescription medicaiton within 1 month of the study